PAUL COOLEY: Open Payments
NPI 1154088268 · PITTSBURGH, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$303 in 13 payments from 7 companies in 2025. Trend: 2023 $326 · 2024 $312 · 2025 $303
Food & beverage: $303
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 4 | $102 |
| Novo Nordisk Inc | 3 | $67 |
| PFIZER INC. | 2 | $38 |
| GlaxoSmithKline, LLC. | 1 | $28 |
| Alkermes, Inc. | 1 | $27 |
| SHIELD THERAPEUTICS INC | 1 | $24 |
| Lilly USA, LLC | 1 | $18 |
Products named: QULIPTA, VRAYLAR, TRELEGY ELLIPTA, Wegovy, VIVITROL, ACCRUFER, ELIQUIS, Ozempic.
Industry payments across PA — which companies pay providers there.
